AbbVie Presents Phase 1 Data for Investigational Weight Management Drug ABBV-295

AbbVie presented detailed Phase 1 study results for its investigational drug ABBV-295, a long-acting amylin analog, at the European Association for the Study of Diabetes (EASD) Annual Meeting. The study evaluated the tolerability, pharmacokinetics, and pharmacodynamics of the compound in adults with a mean body mass index (BMI) below 30 kg/m2.

The findings indicated that ABBV-295 achieved a half-life of approximately 11 to 12 days, with dose-proportional increases in plasma exposure. This pharmacokinetic profile supports the evaluation of less frequent dosing intervals, including every-other-week and monthly regimens, in addition to weekly administration.

Across all evaluated dose levels, ABBV-295 demonstrated meaningful body weight reduction over 12 to 13 weeks. Least-squares mean weight reductions ranged from -7.8% to -9.8% in once-weekly cohorts and -9.7% in an every-other-week cohort, compared to approximately -0.3% in the placebo group. The drug exhibited a favorable tolerability profile, with most adverse events reported as mild.

Commonly reported adverse events included decreased appetite, fatigue, headache, nausea, and diarrhea. No serious treatment-emergent adverse events were reported. AbbVie plans to advance ABBV-295, which targets the amylin pathway and represents a non-incretin mechanism, into Phase 2 development for chronic weight management.